Recent studies have identified DNA methylation signatures in the white blood cells as potential biomarkers for breast cancer (BC) in the European population. Here, we investigated the association between BC and blood-based methylation of cluster of differentiation 160 (CD160), inositol-3-phosphate synthase 1 (ISYNA1) and RAD51 paralog B (RAD51B) genes in the Chinese population. Peripheral blood samples were collected from two independent case-control studies with a total of 272 sporadic early-stage BC cases (76.5% at stage I&II) and 272 cancer-free female controls. Mass spectrometry was applied to quantitatively measure the levels of DNA methylation. The logistic regression and non-parametric tests were used for the statistical analyses. In contrast to the protective effects reported in European women, we reported the blood-based hypomethylation in CD160, ISYNA1 and RAD51B as risk factors for BC in the Chinese population (CD160_CpG_3, CD160_CpG_4/cg20975414, ISYNA1_CpG_2, RAD51B_CpG_3 and RAD51B_CpG_4; odds ratios (ORs) per -10% methylation ranging from 1.08 to 1.67, p < 0.05 for all). Moreover, hypomethylation of CD160, ISYNA1 and RAD51B was significantly correlated with age, BC subtypes including estrogen receptor (ER)-negative BC tumors, triple negative tumors, BC cases with larger size, advanced stages and more lymph node involvement. Our results supported the report in European women that BC is associated with altered methylation of CD160, ISYNA1 and RAD51B in the peripheral blood, although the effects are opposite in the Chinese population. The difference between the two populations may be due to variant genetic background or life styles, implicating that the validations of epigenetic biomarkers in variant ethnic groups are warranted.
e20500 Background: Lung cancer (LC) is the leading cause of cancer-related death. Although low-dose computed tomography (LDCT) is a routine clinical test for early detection of LC, it can introduce excessive false positives. DNA specific methylation identification in peripheral blood can be used for noninvasive diagnosis and monitoring. Therefore, We applied a candidate approach and assess the association between blood-based FGR methylation and the risk of lung cancer in a case–control cohort. Methods: A total of 426 patients with LC and 428 age-and sex-matched healthy controls were recruited from two hospitals to collect peripheral blood and clinical information. The methylation levels of four CPG sites in FGR gene were determined by quantitative mass spectrometry. Linear regression models were used to estimate the association between DNA methylation site levels and lung cancer. And stratified analysis of age and sex. Results: It was found that the hypermethylation of FGR_CPG1 and FGR_CPG2 was associated with early LC (OR = 1.60 (95%CI: 1.35, 1.89, p = 5.35E-08) and 1.08 (95%CI: 1.01, 1.16, p = 3.58E-02), respectively). These associations persist in patients with very early LC (stage I). Stratified analysis showed that the association between hypermethylation of FGR_CPG2 and LC was only found in men and subjects younger than 55 years of age. Conclusions: This work reveals a novel association between aberrant FGR gene methylation in blood and early LC. These results suggest that FGR gene methylation may be used to predict early lung cancer and provide guidance for the prevention and control of lung cancer.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.